Roseman University Launches Roseman Bioventures, a 120,000-Square-Foot Life Science Incubator in Las Vegas

Roseman University Launches Roseman Bioventures, a 120,000-square-foot Life Science Incubator in Las Vegas Roseman University of Health Sciences today announced the launch of Roseman Bioventures in Las Vegas to accelerate the translation of scientific breakthroughs into therapies and technologies that…

Read MoreRoseman University Launches Roseman Bioventures, a 120,000-Square-Foot Life Science Incubator in Las Vegas
Element Science

Element Science Recognized on Fast Company’s 2026 List of the World’s Most Innovative Companies

Element Science Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 Element Science, a pioneering health technology company that has developed the Jewel® Patch Wearable Cardioverter Defibrillator (Patch-WCD) to monitor and protect high-risk cardiovascular patients from sudden…

Read MoreElement Science Recognized on Fast Company’s 2026 List of the World’s Most Innovative Companies
Houston’s

Houston’s Rice WaTER Institute Partners with Israel’s IDE Technologies to Advance Water Treatment Innovations

Houston’s Rice WaTER Institute and Israel’s IDE Technologies Collaborate to Advance Water Treatment Solutions IDE Technologies, a world leader in desalination and advanced water treatment solutions, and Rice University’s Water Technologies Entrepreneurship and Research (WaTER) Institute, a multidisciplinary center advancing…

Read MoreHouston’s Rice WaTER Institute Partners with Israel’s IDE Technologies to Advance Water Treatment Innovations
First Patient

First Patient Receives Dose in New Study Evaluating Innovative Canadian-Developed Drug to Prevent Brain Injury in Hemodialysis Patients

First Patient Dosed in New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients The first patient has been treated in a unique clinical trial to evaluate the safety and efficacy of a novel pharmacologic intervention…

Read MoreFirst Patient Receives Dose in New Study Evaluating Innovative Canadian-Developed Drug to Prevent Brain Injury in Hemodialysis Patients
iXCells

iXCells joins global effort to study chemo toxicity in human organoids.

iXCells Biotechnologies Joins International Collaboration to Evaluate Chemotherapeutic Toxicity in Human Organoids partnership with Rosebud1 and funded by Incite, the project will initially focus on predicting toxicity in heart, liver, and kidney tissue models, to develop personalized, multi-organ toxicity profiles for…

Read MoreiXCells joins global effort to study chemo toxicity in human organoids.
Skeyeon

Skeyeon secures patent for VLEO satellite imaging and real-time data delivery.

Skeyeon Secures Key Patent for Very-Low Earth Orbit Satellite Constellations with Onboard Imaging and Direct-to-Ground Data Delivery Enabling Near-Real-Time Earth Observation Skeyeon, Inc., today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,559,451 B2,…

Read MoreSkeyeon secures patent for VLEO satellite imaging and real-time data delivery.
Sinopia Biosciences

Sinopia Biosciences wins NCI grant to advance LEADS® oncology platform.

Sinopia Biosciences Awarded NCI Grant to Advance LEADS® Drug Discovery Platform for Oncology Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary LEADS® (LEarn And DiScover) drug discovery platform, today announced it has been awarded a…

Read MoreSinopia Biosciences wins NCI grant to advance LEADS® oncology platform.
NImmune

NImmune to present LANCL2 therapeutic data at IMMUNOLOGY2026.

NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026 NImmune Biopharma a private late-stage precision inflammation and immunology (“I&I”) biopharmaceutical company, will present first-ever preclinical and translational data demonstrating the…

Read MoreNImmune to present LANCL2 therapeutic data at IMMUNOLOGY2026.
Element Science

Lineage initiates a new cell therapy program targeting corneal endothelial disease.

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease Lineage Cell Therapeutics, Inc. a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the expansion of its cell transplant pipeline…

Read MoreLineage initiates a new cell therapy program targeting corneal endothelial disease.